CLR 131 Helps Heavily Treated Multiple Myeloma Patients, Phase 2 Data Show
Cellectar Biosciences’ lead candidate CLR 131 safely…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
New CAR T-cell Therapy Shows Early Promise Against Multiple Myeloma in Lab Study
A new CAR T-cell therapy for …
Xpovio May Soon Be Available in Israel and Palestinian Authority, Karyopharm Says
Xpovio (selinexor), a treatment for advanced multiple…
Darzalex Combo Leads to Durable Responses in Patients With Advanced Multiple Myeloma, Follow-up Data Show
Janssen‘s Darzalex (daratumumab) in combination with…
Kleo’s KP1237 Therapy Soon Will Enter Clinical Testing, Following FDA’s Grant of New Drug Status
KP1237, an experimental therapy by Kleo Pharmaceutical…
Phase 1/2 Trial of ‘Off-the-shelf’ CAR T-cell Therapy for Multiple Myeloma to Open Soon
A clinical trial is soon to begin testing Precision…
